, Shortages of medicines: a complex global challenge

A. V. Gundlapalli, S. E. Beekmann, D. R. Graham, and P. M. Polgreen, Infectious Diseases Society of America's Emerging Infections Network. Perspectives and concerns regarding antimicrobial agent shortages among infectious disease specialists, Diagn Microbiol Infect Dis. mars, vol.75, issue.3, pp.256-265, 2013.

R. Kaakeh, B. V. Sweet, C. Reilly, C. Bush, S. Deloach et al., Impact of drug shortages on U.S. health systems, Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm, vol.68, pp.1811-1820, 2011.

, Special Issue: Drug shortages: National Survey Reveals High Level of Frustration, Low Level of Safety

J. Garau, D. P. Nicolau, B. Wullt, and M. Bassetti, Antibiotic stewardship challenges in the management of community-acquired infections for prevention of escalating antibiotic resistance, J Glob Antimicrob Resist. 1 déc, vol.2, issue.4, pp.245-53, 2014.

M. R. Akpan, R. Ahmad, N. A. Shebl, and D. Ashiru-oredope, Antibacterial agents in clinical development, A Review of Quality Measures for Assessing the Impact of Antimicrobial Stewardship Programs in Hospitals. Antibiotics, vol.13, 2017.

. Disponible, , vol.0187, p.1

J. J. Marr, H. L. Moffet, and C. M. Kunin, From the Infectious Diseases Society of America Guidelines for Improving the Use of Antimicrobial Agents in Hospitals: A Statement by the Infectious Diseases Society of America, J Infect Dis. 1 mai, vol.157, issue.5, pp.869-76, 1988.

O. J. Dyar, B. Huttner, J. Schouten, and C. Pulcini, What is antimicrobial stewardship?, Clin Microbiol Infect, vol.23, issue.11, pp.793-801, 2017.

E. J. Septimus and R. C. Owens, Need and potential of antimicrobial stewardship in community hospitals, Clin Infect Dis Off Publ Infect Dis Soc Am. août, vol.53, issue.1, pp.8-14, 2011.

A. V. Gundlapalli, S. E. Beekmann, D. R. Graham, and P. M. Polgreen, Antimicrobial Agent Shortages: The New Norm for Infectious Diseases Physicians. Open Forum Infect Dis, vol.5, 2018.

P. Global,

, Antimicrobial Consumption and Resistance

, Disponible

. Pfizer, Monographie de produit -Tazocin

K. E. Barber, A. M. Bell, T. King, S. Parham, J. J. Stover et al., Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs, Braz J Infect Dis, vol.20, issue.6, pp.631-635, 2016.

S. T. King, K. E. Barber, J. J. Parham, and K. R. Stover, Shifts in antimicrobial consumption and infection rates before and during a piperacillin/tazobactam shortage, J Glob Antimicrob Resist, vol.11, pp.111-114, 2017.

W. K. Alston and J. W. Ahern, Increase in the rate of nosocomial Clostridium difficile-associated diarrhoea during shortages of piperacillin-tazobactam and piperacillin, J Antimicrob Chemother. mars, vol.53, issue.3, pp.549-50, 2004.

A. E. Gross, R. S. Johannes, V. Gupta, Y. P. Tabak, A. Srinivasan et al., The Effect of a Piperacillin/Tazobactam Shortage on Antimicrobial Prescribing and Clostridium difficile Risk in 88 US Medical Centers, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 août, vol.65, issue.4, pp.613-621, 2017.

C. B. Cunha, Antimicrobial Stewardship Programs: Principles and Practice, Med Clin North Am. sept, vol.102, issue.5, pp.797-803, 2018.

P. Bogaert, T. Bochenek, A. Prokop, and A. Pilc, A Qualitative Approach to a Better Understanding of the Problems Underlying Drug Shortages, as Viewed from Belgian, French and the European Union's Perspectives, PloS One, vol.10, issue.5, p.125691, 2015.

E. De-weerdt, S. Simoens, M. Casteels, and I. Huys, Toward a European definition for a drug shortage: a qualitative study, Front Pharmacol, vol.6, 2015.

, Décret n° 2012-1096 du 28 septembre 2012 relatif à l'approvisionnement en médicaments à usage humain, 2012.

, Santé Canada

P. De-drogues-au and C. , , vol.9, 2014.

. Disponible,

. Fda, Review of FDA's Approach to Medical Product Shortages, 2011.

K. Pauwels, S. Simoens, M. Casteels, and I. Huys, Insights into European drug shortages: a survey of hospital pharmacists, PloS One, vol.10, issue.3, p.119322, 2015.

. Duke, FDA drug shortages presentation

, Strategic plan for preventing and mitigating drug shortages

. Disponible,

V. Jensen, Preventing and mitigating drug shortages -FDA's and manufacturers' roles, Am J Health Syst Pharm. 1 juin, vol.75, issue.11, pp.816-836, 2018.

, Shortages of cancer drugs in the USA, Lancet Oncol. 1 avr, vol.12, issue.4, p.313, 2011.

A. E. Rider, D. J. Templet, M. J. Daley, C. Shuman, and L. V. Smith, Clinical dilemmas and a review of strategies to manage drug shortages, J Pharm Pract. juin, vol.26, issue.3, pp.183-91, 2013.

E. R. Fox, A. Birt, K. B. James, H. Kokko, S. Salverson et al., ASHP Guidelines on Managing Drug Product Shortages in Hospitals and Health Systems, Am J Health Syst Pharm. 1 août, vol.66, issue.15, pp.1399-406, 2009.

S. Dill and J. Ahn, Drug shortages in developed countries--reasons, therapeutic consequences, and handling, Eur J Clin Pharmacol. déc, vol.70, issue.12, pp.1405-1417, 2014.

. Ims-ihi, Drug Shortages Report Final

S. Barlas, Severe drug shortages impose heavy costs on hospital pharmacies: senate bill might help ? or not, P T Peer-Rev J Formul Manag. mai, vol.36, issue.5, pp.242-302, 2011.

C. L. Ventola, The Drug Shortage Crisis in the United States, vol.36, pp.740-57, 2011.

M. Videau, L. Chemali, C. Stucki, M. Saavedra-mitjans, S. Largana et al., Drug Shortages in Canada and Selected European Countries: A Cross-Sectional, Institution-Level Comparison, Can J Hosp Pharm. févr, vol.72, issue.1, pp.7-15, 2019.

J. G. Alspach, The Drug Shortage What Critical Care Nurse Readers Report, Crit Care Nurse. 10 janv, vol.32, issue.5, pp.11-14, 2012.

, An Evaluation of Medicines Shortages in Europe with a more in-depth review of these in France

C. Research, Drug Shortages Infographic. FDA [En ligne, 2019.

J. Woodcock and M. Wosinska, Economic and technological drivers of generic sterile injectable drug shortages, Clin Pharmacol Ther. févr, vol.93, issue.2, pp.170-176, 2013.

K. Pauwels, I. Huys, M. Casteels, and S. Simoens, Drug shortages in European countries: a trade-off between market attractiveness and cost containment? BMC, Health Serv Res. 26 sept, vol.14, issue.1, p.438, 2014.

, Guide pour la déclaration de pénuries et de cessations de la vente de drogues

, Boîte à outils multilatérale pour mieux comprendre les interventions aux pénuries de médicaments au Canada et en accroître la transparence

. Disponible,

L. Loi-sur and . Pharmacie,

, EHAP, 2019.

N. Miljkovi?, N. Gibbons, A. Batista, R. W. Fitzpatrick, J. Underhill et al., Results of EAHP's 2018 Survey on Medicines Shortages, Eur J Hosp Pharm. 4 févr, 2019.

, Guidance on detection and notification of shortages of medicinal products for Marketing Authorisation Holders in the Union

, Lutter contre les pénuries et améliorer la disponibilité des médicaments en France -Feuille de route, pp.2019-2022

J. E. Mcgowan and D. N. Gerding, Does antibiotic restriction prevent resistance, New Horiz Baltim Md. août, vol.4, issue.3, pp.370-376, 1996.

I. M. Gould, Stewardship of antibiotic use and resistance surveillance: the international scene, J Hosp Infect. 1 déc, vol.43, pp.253-60, 1999.

D. M. Shlaes, D. N. Gerding, J. F. John, W. A. Craig, D. L. Bornstein et al., Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals, Clin Infect Dis Off Publ Infect Dis Soc Am. sept, vol.25, issue.3, pp.584-99, 1997.

N. Fishman, S. America, . America-ids-of, and P. Society, Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS), Infect Control Hosp Epidemiol. avr, vol.33, issue.4, pp.322-329, 2012.

T. F. Barlam, S. E. Cosgrove, L. M. Abbo, C. Macdougall, A. N. Schuetz et al., Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.15, issue.10, pp.51-77, 2016.

O. J. Dyar, C. Obua, S. Chandy, Y. Xiao, S. Lundborg et al., Using antibiotics responsibly: are we there yet?, Future Microbiol. 1 août, vol.11, issue.8, pp.1057-71, 2016.

D. Plachouras and E. Iosifidis, Europäisches Zentrum für die Prävention und die Kontrolle von Krankheiten. Proposals for EU guidelines on the prudent use of antimicrobials in humans, 2017.

, Lignes directrices de l'UE pour une utilisation prudente des antimicrobiens en santé humain, 2017.

, Rôle du pharmacien d'établissement en infectiologie : Données probantes. Document élaboré par le Regroupement de pharmaciens experts en infectiologie, Association des pharmaciens des établissements de santé du Québec, p.52, 2018.

M. Gilchrist, P. Wade, D. Ashiru-oredope, P. Howard, J. Sneddon et al., Antimicrobial Stewardship from Policy to Practice: Experiences from UK Antimicrobial Pharmacists, Infect Dis Ther. sept, vol.4, issue.1, pp.51-64, 2015.

J. Garau and M. Bassetti, Role of pharmacists in antimicrobial stewardship programmes, Int J Clin Pharm. oct, vol.40, issue.5, pp.948-52, 2018.

H. Autorité-de-santé,

, Stratégie d'antibiothérapie et prévention des résistances bactériennes en établissement de santé

M. T. Bessesen, A. Ma, D. Clegg, R. V. Fugit, A. Pepe et al., Antimicrobial Stewardship Programs: Comparison of a Program with Infectious Diseases Pharmacist Support to a Program with a Geographic Pharmacist Staffing Model, Hosp Pharm. juin, vol.50, issue.6, pp.477-83, 2015.

C. A. Diazgranados, Prospective audit for antimicrobial stewardship in intensive care: impact on resistance and clinical outcomes, Am J Infect Control. août, vol.40, issue.6, pp.526-535, 2012.

M. M. Griffith, J. A. Patel, S. H. Sutton, M. K. Bolon, J. S. Esterly et al., Prospective Approach to Managing Antimicrobial Drug Shortages, Infect Control Hosp Epidemiol. juill, vol.33, issue.7, pp.745-52, 2012.

K. Hsueh, M. Reyes, T. Krekel, E. Casabar, D. J. Ritchie et al., Effective Antibiotic Conservation by Emergency Antimicrobial Stewardship During a Drug Shortage, Infect Control Hosp Epidemiol. mars, vol.38, issue.3, pp.356-365, 2017.

F. Foolad, A. M. Huang, C. T. Nguyen, L. Colyer, M. Lim et al., A multicentre stewardship initiative to decrease excessive duration of antibiotic therapy for the treatment of communityacquired pneumonia, J Antimicrob Chemother, vol.73, issue.5, pp.1402-1409, 2018.

S. E. Bond, C. S. Boutlis, W. W. Yeo, and S. Miyakis, Impact of an antimicrobial stewardship intervention on appropriateness of prescribing for community-acquired pneumonia in an Australian regional hospital, Intern Med J, vol.47, issue.5, pp.582-587, 2017.

E. Avdic, L. A. Cushinotto, A. H. Hughes, A. R. Hansen, L. E. Efird et al., Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for communityacquired pneumonia, Clin Infect Dis Off Publ Infect Dis Soc Am. juin, vol.54, issue.11, pp.1581-1588, 2012.

D. X. Li, M. A. Ferrada, E. Avdic, P. D. Tamma, and S. E. Cosgrove, Sustained Impact of an Antibiotic Stewardship Intervention for Community-Acquired Pneumonia, Infect Control Hosp Epidemiol, vol.37, issue.10, pp.1243-1249, 2016.

K. Gordon, R. Stevens, B. Westley, and L. Bulkow, Impact of an antimicrobial stewardship program on outcomes in patients with community-acquired pneumonia admitted to a tertiary community hospital, Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 1 juin, vol.75, issue.11, pp.42-50, 2018.

J. Carratalà, C. Garcia-vidal, L. Ortega, N. Fernández-sabé, M. Clemente et al., Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial, Arch Intern Med. 25 juin, vol.172, issue.12, pp.922-930, 2012.

C. M. Kozma, M. Dickson, M. K. Raut, S. Mody, A. C. Fisher et al., Economic benefit of a 1-day reduction in hospital stay for community-acquired pneumonia (CAP), J Med Econ. 1 déc, vol.13, issue.4, pp.719-746, 2010.

J. M. Hurst and J. A. Bosso, Antimicrobial stewardship in the management of community-acquired pneumonia, Curr Opin Infect Dis. avr, vol.26, issue.2, pp.184-192, 2013.

D. Viasus, M. Vecino-moreno, J. Hoz, and J. Carratalà, Antibiotic stewardship in communityacquired pneumonia, Expert Rev Anti Infect Ther. 3 avr, vol.15, issue.4, pp.351-360, 2017.

H. Yamana, H. Matsui, T. Tagami, J. Hirashima, K. Fushimi et al., De-escalation versus continuation of empirical antimicrobial therapy in community-acquired pneumonia, J Infect, vol.73, issue.4, pp.314-339, 2016.

L. A. Mandell, Community-acquired pneumonia: An overview, Postgrad Med. août, vol.127, issue.6, pp.607-622, 2015.

Z. Athanassa, G. Makris, G. Dimopoulos, and M. E. Falagas, Early Switch to Oral Treatment in Patients with Moderate to Severe Community-Acquired Pneumonia, Drugs. 1 déc, vol.68, issue.17, pp.2469-81, 2008.

E. M. Mortensen, M. Restrepo, A. Anzueto, and J. Pugh, Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia, Am J Med, vol.117, issue.10, pp.726-757, 2004.

C. Mccabe, C. Kirchner, H. Zhang, J. Daley, and D. N. Fisman, Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules, Arch Intern Med. 14 sept, vol.169, issue.16, pp.1525-1556, 2009.

H. M. Bryson and R. N. Brogden, Piperacillin/Tazobactam. Drugs. 1 mars, vol.47, issue.3, pp.506-541, 1994.

L. L. Schoonover, D. J. Occhipinti, K. A. Rodvold, and L. H. Danziger, Piperacillin/tazobactam: a new betalactam/beta-lactamase inhibitor combination, Ann Pharmacother. mai, vol.29, issue.5, pp.501-515, 1995.

C. M. Perry and A. Markham, Piperacillin/Tazobactam: An Updated Review of its Use in the Treatment of Bacterial Infections, Drugs, vol.57, issue.5, pp.805-848, 1999.

. Has and . Tazocilline,

. Disponible,

K. P. Daniel and L. C. Krop, Piperacillin-Tazobactam: a new beta-lactam-beta-lactamase inhibitor combination, Pharmacotherapy. avr, vol.16, issue.2, pp.149-62, 1996.

D. J. Occhipinti, S. L. Pendland, L. L. Schoonover, E. B. Rypins, L. H. Danziger et al., Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens, Antimicrob Agents Chemother, vol.41, issue.11, pp.2511-2518, 1997.

F. Sörgel and M. Kinzig, The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam, J Antimicrob Chemother. 1 janv, vol.31, pp.39-60, 1993.

, Avis de la commission de transparence -Tazocilline, HAS, 2016.

. Disponible,

, Base de données publique des médicaments

, Résumé des caractéristiques du produit -TAZOCILLINE 4 g/0,5 g, poudre pour solution pour perfusion, vol.25

M. N. Mendez, L. Gibbs, R. A. Jacobs, C. E. Mcculloch, L. Winston et al., Impact of a Piperacillin-Tazobactam Shortage on Antimicrobial Prescribing and the Rate of Vancomycin-Resistant Enterococci and Clostridium difficile Infections, Pharmacother J Hum Pharmacol Drug Ther, vol.26, issue.1, pp.61-68, 2006.

M. H. Wilcox, J. Freeman, W. Fawley, S. Mackinlay, A. Brown et al., Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea, J Antimicrob Chemother. 1 juill, vol.54, issue.1, pp.168-72, 2004.

, Organisation mondiale de la Santé

, The top 10 causes of death

. Disponible,

, Revue générale des pneumonies -Troubles pulmonaires

. Ameli and . Fr,

, Pneumonie : définition et facteurs de risque

. Disponible,

G. Mackenzie, The definition and classification of pneumonia, National Heart, Lung, and Blood Institute, vol.22

. Disponible,

J. Broulette, H. Yu, B. Pyenson, K. Iwasaki, and R. Sato, The Incidence Rate and Economic Burden of Community-Acquired Pneumonia in a Working-Age Population, Am Health Drug Benefits, vol.6, issue.8, pp.494-503, 2013.

N. K. Brar and M. S. Niederman, Management of community-acquired pneumonia: a review and update, Ther Adv Respir Dis. 1 févr, vol.5, issue.1, pp.61-78, 2011.

J. S. Lee, D. L. Giesler, W. F. Gellad, and M. J. Fine, Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review, JAMA. 9 févr, vol.315, issue.6, pp.593-602, 2016.

L. A. Mandell, R. G. Wunderink, A. Anzueto, J. G. Bartlett, G. D. Campbell et al., Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults, Clin Infect Dis. 1 mars, vol.44, issue.Supplement_2, pp.27-72, 2007.

M. Burk, K. El-kersh, M. Saad, T. Wiemken, J. Ramirez et al., Viral infection in communityacquired pneumonia: a systematic review and meta-analysis, Eur Respir Rev Off J Eur Respir Soc. juin, vol.25, issue.140, pp.178-88, 2016.

G. Waterer, Community-acquired Pneumonia: A Global Perspective, Semin Respir Crit Care Med. 13 déc, vol.37, issue.06, pp.799-805, 2016.

, Guide d'usage optimal des antibiotiques dans la pneumonie acquise en communauté chez l'adulte, INESSS, 2017.

A. C. Kalil, M. L. Metersky, M. Klompas, J. Muscedere, D. A. Sweeney et al., Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the, Clin Infect Dis. 1 sept, vol.63, issue.5, pp.61-111, 2016.

E. Shebl, P. G. Gulick, and . Pneumonia, Treasure Island (FL) : StatPearls Publishing, StatPearls, 2019.

J. D. Chalmers, C. Rother, W. Salih, and S. Ewig, Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis, Clin Infect Dis Off Publ Infect Dis Soc Am. févr, vol.58, issue.3, pp.330-339, 2014.

D. Chatellier, S. Chauvet, and R. Robert, Pneumopathies d'inhalation. Réanimation. 1 juin, vol.18, issue.4, pp.328-361, 2009.

, Pneumopathie et pneumonie d'inhalation -Troubles pulmonaires

, Guide de traitement de la pneumonie nosocomiale et d'aspiration chez l'adulte

D. M. Musher and A. R. Thorner, Community-Acquired Pneumonia, N Engl J Med, vol.371, issue.17, pp.1619-1647, 2014.

J. Ruhe and D. Mildvan, Does empirical therapy with a fluoroquinolone or the combination of a ?lactam plus a macrolide result in better outcomes for patients admitted to the general ward?, Infect Dis Clin North Am. mars, vol.27, issue.1, pp.115-147, 2013.

K. Thiessen, A. E. Lloyd, M. J. Miller, J. Homco, B. Gildon et al., Assessing guideline-concordant prescribing for community-acquired pneumonia, Int J Clin Pharm. 1 août, vol.39, issue.4, pp.674-682, 2017.

S. T. Kumar, A. Yassin, T. Bhowmick, and D. Dixit, Recommendations From the 2016 Guidelines for the Management of Adults With Hospital-Acquired or Ventilator-Associated Pneumonia, P T Peer-Rev J Formul Manag. déc, vol.42, issue.12, pp.767-72, 2017.

, WHO Collaborating Centre for Drug Statistics Methodology

A. Index, , 2019.

, International Statistical Classification of Diseases and Related Health Problems, 2016.

A. M. Morris, Antimicrobial Stewardship Programs: Appropriate Measures and Metrics to Study their Impact, Curr Treat Options Infect Dis, vol.6, issue.2, pp.101-113, 2014.

R. E. Polk, C. Fox, A. Mahoney, J. Letcavage, and C. Macdougall, Measurement of Adult Antibacterial Drug Use in 130 US Hospitals: Comparison of Defined Daily Dose and Days of Therapy, Clin Infect Dis. 1 mars, vol.44, issue.5, pp.664-70, 2007.

K. A. Brown, N. Khanafer, N. Daneman, and D. N. Fisman, Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection, Antimicrob Agents Chemother. 1 mai, vol.57, issue.5, pp.2326-2358, 2013.

C. Slimings and T. V. Riley, Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis, J Antimicrob Chemother. avr, vol.69, issue.4, pp.881-91, 2014.

M. E. Charlson, P. Pompei, K. L. Ales, and C. R. Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, vol.40, issue.5, pp.373-83, 1987.

H. Quan, B. Li, C. M. Couris, K. Fushimi, P. Graham et al., Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries, Am J Epidemiol. 15 mars, vol.173, issue.6, pp.676-82, 2011.

V. De-groot, H. Beckerman, G. J. Lankhorst, and L. M. Bouter, How to measure comorbidity. a critical review of available methods, J Clin Epidemiol. mars, vol.56, issue.3, pp.221-230, 2003.

P. A. Harris, R. Taylor, R. Thielke, J. Payne, N. Gonzalez et al., Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform. avr, vol.42, issue.2, pp.377-81, 2009.

P. A. Harris, R. Taylor, B. L. Minor, V. Elliott, M. Fernandez et al., The REDCap consortium: Building an international community of software platform partners, J Biomed Inform. juill, vol.95, p.103208, 2019.

, Surveillance for antimicrobial use and antimicrobial resistance options. Protocols: Antimicrobial use and resistance (AUR) module, Centers for Disease Control and Prevention. National Healthcare Safety Network (NHSN), 2015.

S. R. Johnk, C. J. Grindeland, D. D. Leedahl, P. J. Carson, and N. D. Leedahl, Impact of a multicenter stewardship-targeted carbapenem justification requirement on the use of carbapenems in 23 hospitals, JACCP J Am Coll Clin Pharm. 1 févr, vol.2, issue.1, pp.53-60, 2019.

J. Vincent, J. Rello, J. Marshall, E. Silva, A. Anzueto et al., International Study of the Prevalence and Outcomes of Infection in Intensive Care Units, JAMA. 2 déc, vol.302, issue.21, pp.2323-2332, 2009.

C. Plüss-suard, A. Pannatier, C. Ruffieux, A. Kronenberg, K. Mühlemann et al., Changes in the Use of Broad-Spectrum Antibiotics after Cefepime Shortage: a Time Series Analysis, Antimicrob Agents Chemother. 1 févr, vol.56, issue.2, pp.989-94, 2012.

T. L. Hagen, M. A. Hertz, G. B. Uhrin, M. Dalager-pedersen, H. C. Schønheyder et al., Adherence to local antimicrobial guidelines for initial treatment of community-acquired infections, Dan Med J. juin, vol.64, issue.6, 2017.

S. Gattarello, S. Ramírez, J. R. Almarales, B. Borgatta, L. Lagunes et al., Causes of nonadherence to therapeutic guidelines in severe community-acquired pneumonia, Rev Bras Ter Intensiva. mars, vol.27, issue.1, pp.44-50, 2015.

S. E. Cosgrove, S. K. Seo, M. K. Bolon, K. A. Sepkowitz, M. W. Climo et al., Evaluation of postprescription review and feedback as a method of promoting rational antimicrobial use: a multicenter intervention, Infect Control Hosp Epidemiol. avr, vol.33, issue.4, pp.374-80, 2012.

K. L. Buising, K. A. Thursky, M. B. Robertson, J. F. Black, A. C. Street et al., Electronic antibiotic stewardship--reduced consumption of broad-spectrum antibiotics using a computerized antimicrobial approval system in a hospital setting, J Antimicrob Chemother. sept, vol.62, issue.3, pp.608-624, 2008.

A. L. Pakyz, M. Oinonen, and R. E. Polk, Relationship of Carbapenem Restriction in 22 University Teaching Hospitals to Carbapenem Use and Carbapenem-Resistant Pseudomonas aeruginosa, Antimicrob Agents Chemother. mai, vol.53, issue.5, pp.1983-1989, 2009.

J. M. Mehta, K. Haynes, E. P. Wileyto, J. S. Gerber, D. R. Timko et al., Comparison of prior authorization and prospective audit with feedback for antimicrobial stewardship, Infect Control Hosp Epidemiol. sept, vol.35, issue.9, pp.1092-1101, 2014.

J. J. Rahal, C. Urban, D. Horn, K. Freeman, S. Segal-maurer et al., Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella, JAMA, vol.280, issue.14, pp.1233-1240, 1998.